We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+42.81%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.08B
AUM Growth
+$85.4M
Cap. Flow
-$147M
Cap. Flow %
-13.59%
Top 10 Hldgs %
60.85%
Holding
62
New
9
Increased
7
Reduced
15
Closed
21
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1 year
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$57.7M
2
XNCR icon
Xencor
XNCR
+$35.6M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$28.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$24M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$17.6M

Top Sells

Rank Stock Value
1
KYNB icon
Kyntra Bio
KYNB
+$73.6M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$44.7M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$39.2M
4
ASND icon
Ascendis Pharma A/S
ASND
+$27.9M
5
ASMB icon
Assembly Biosciences
ASMB
+$26.4M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
2 Miscellaneous 14.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RUBY
26
DELISTED
Rubius Therapeutics, Inc
RUBY
$11.7M 1.08%
646,228
+54,100
+9% +$830K
2018 Q3
2 quarters
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$5.95B
$11M 1.01%
400,838
– –
2018 Q4
1 quarter
SURF
28
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$10.8M 1%
2,263,488
+2,160
+0.1% +$10.6K
2018 Q2
3 quarters
KYNB icon
29
Kyntra Bio
KYNB
$20.5M
$9.15M 0.84%
6,735
-54,247
-89% -$73.6M
2014 Q4
17 quarters
PRTA icon
30
Prothena Corp
PRTA
$431M
$8.81M 0.81%
726,519
-111,700
-13% -$1.39M
2018 Q4
1 quarter
RCKT icon
31
Rocket Pharmaceuticals
RCKT
$247M
$7.89M 0.73%
450,000
– –
2018 Q4
1 quarter
ABUS icon
32
Arbutus Biopharma
ABUS
$840M
$7.78M 0.72%
2,172,883
-1,108,619
-34% -$4.26M
2018 Q3
2 quarters
KDNY
33
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$7.72M 0.71%
+387,878
New +$6.76M
2019 Q1
0 quarters
UBX icon
34
DELISTED
Unity Biotechnology
UBX
$7.35M 0.68%
90,661
-6,050
-6% -$686K
2018 Q2
3 quarters
SRRK icon
35
Scholar Rock
SRRK
$4.83B
$6.36M 0.59%
338,668
-1,135,560
-77% -$20M
2018 Q2
3 quarters
NGNE icon
36
Neurogene
NGNE
$470M
$6.11M 0.56%
113,294
– –
2018 Q2
3 quarters
CRIS icon
37
Curis
CRIS
$982K
$5.93M 0.55%
7,456
– –
2018 Q4
1 quarter
ZLAB icon
38
Zai Lab
ZLAB
$2.65B
$2.32M 0.21%
78,519
-490,858
-86% -$13.4M
2018 Q3
2 quarters
VCEL icon
39
Vericel Corp
VCEL
$2.04B
$2.29M 0.21%
+131,001
New +$2.4M
2019 Q1
0 quarters
SNNA
40
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$1.86M 0.17%
+800,000
New +$2.17M
2019 Q1
0 quarters
ARVN icon
41
Arvinas
ARVN
$460M
$738K 0.07%
50,000
– –
2018 Q3
2 quarters
ACRS icon
42
Aclaris Therapeutics
ACRS
$487M
– –
-613,728
Closed -$4.54M –
AFMD icon
43
DELISTED
Affimed
AFMD
– –
-15,822
Closed -$492K –
ASND icon
44
CALL
Ascendis Pharma A/S
ASND
$14.8B
– –
-250,400
Closed -$15.7M –
CORT icon
45
Corcept Therapeutics
CORT
$11.7B
– –
-166,005
Closed -$2.22M –
CRVS icon
46
Corvus Pharmaceuticals
CRVS
$796M
– –
-295,420
Closed -$1.08M –
DVAX icon
47
DELISTED
Dynavax Technologies
DVAX
– –
-140,118
Closed -$1.28M –
GILD icon
48
CALL
Gilead Sciences
GILD
$193B
– –
-285,100
Closed -$17.8M –
IONS icon
49
Ionis Pharmaceuticals
IONS
$7.16B
– –
-725,326
Closed -$39.2M –
NKTR icon
50
CALL
Nektar Therapeutics
NKTR
$1.23B
– –
-21,113
Closed -$10.4M –
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2019 Portfolio in Review

As of Q1 2019, EcoR1 Capital held 62 positions worth $1.08B, up 8.5% from $999M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital withdrew a net $147M in Q1 2019, closing 21 positions and reducing 15 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $39.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Ultragenyx Pharmaceutical worth $34.5M.

  • EcoR1 Capital's largest Q1 2019 buy was Ultragenyx Pharmaceutical: 497,899 shares worth $34.5M.
  • EcoR1 Capital added most to CRISPR Therapeutics in Q1 2019, an estimated $57.7M increase.
  • EcoR1 Capital's biggest Q1 2019 reduction was Kyntra Bio, cutting an estimated $73.6M.
  • EcoR1 Capital fully exited Ionis Pharmaceuticals in Q1 2019, selling an estimated $39.2M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $1.08B portfolio in Q1 2019.
  • EcoR1 Capital opened 9 new positions and closed 21 in Q1 2019.
  • EcoR1 Capital's portfolio value rose 8.5% quarter-over-quarter to $1.08B.

Based on EcoR1 Capital's 13F filing for Q1 2019, filed 15 May 2019.